Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices

Implementation Science

Volumn 9, Issue 1, 2014, Pages

  Prasad, Vinay ^a,b   Ioannidis, John P A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bias; Contradiction; De implementation; Divestment; Evidence based medicine; Reversals

Indexed keywords

CLINICAL PRACTICE; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; MASS COMMUNICATION; ORGANIZATION AND MANAGEMENT; PATIENT SAFETY;

DIFFUSION OF INNOVATION; EVIDENCE-BASED MEDICINE; PATIENT SAFETY; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF HEALTH CARE;

EID: 84891786463     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-9-1     Document Type: Editorial

References (31)

1. Elshaug AG, Watt AM, Mundy L, Willis CD. Over 150 potentially low-value health care practices: an Australian study. Med J Aust 2012, 197:556-560. 10.5694/mja12.11083, 23163685.
2. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013, 88:790-798. 10.1016/j.mayocp.2013.05.012, 23871230.
3. Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 2013, 43:469-475. 10.1111/eci.12074, 23521369.
4. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ 2013, 347:f5535. 10.1136/bmj.f5535, 24046286.
5. Winstein KJ. A simple health-care fix fizzles out. The Wall Street Journal 2010, Date Accessed: December 9, 2013 at http://online.wsj.com/news/articles/SB10001424052748703652104574652401818092212.
6. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:312-319. 10.1001/archinternmed.2011.1484, 22371919.
7. Katritsis DG, Ioannidis JPA. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005, 111:2906-2912. 10.1161/CIRCULATIONAHA.104.521864, 15927966.
8. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. PAtterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011, 305:1882-1889. 10.1001/jama.2011.601, 21558519.
9. Siontis GC, Tatsioni A, Katritsis DG, Ioannidis JP. Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis. Am Heart J 2009, 157:695-701. 10.1016/j.ahj.2008.11.023, 19332198.
10. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012, 367:991-1001. 10.1056/NEJMoa1205361, 22924638.
11. Jain R, Kralovic SM, Evans ME, et al. Veterans affairs initiative to prevent methicillin-resistant staphylococcus aureus infections. N Engl J Med 2011, 364:1419-1430. 10.1056/NEJMoa1007474, 21488764.
12. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011, 364:1407-1418. 10.1056/NEJMoa1000373, 3410743, 21488763.
13. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the icu: a randomized trial. JAMA 2013, 310:1571-1580.
14. Ioannidis JA, Prasad V. EValuating health system processes with randomized controlled trials. JAMA Intern Med 2013, 173:1279-1280. 10.1001/jamainternmed.2013.1044, 23689271.
15. Malani PN. Preventing infections in the icu: one size does not fit all. JAMA 2013, 310:1567-1568. 10.1001/jama.2013.277816, 24097192.
16. Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013, 368:2255-2265. 10.1056/NEJMoa1207290, 23718152.
17. El Dib RP, Atallah AN, Andriolo RB. Mapping the Cochrane evidence for decision making in health care. J Eval Clin Pract 2007, 13:689-692. 10.1111/j.1365-2753.2007.00886.x, 17683315.
18. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009, 301:831-841. 10.1001/jama.2009.205, 19244190.
19. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996, 5:513-524. 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9, 9003938.
20. Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol 2013, 9:665-673. 10.1038/nrrheum.2013.134, 23999553.
21. Prasad V, Rho J, Cifu A. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy?. JAMA Intern Med 2013, 1:3.
22. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011, (1):CD001877.
23. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003, 349:237-246. 10.1056/NEJMoa023171, 12867607.
24. Mechanic R, Tompkins C. Lessons learned preparing for medicare bundled payments. N Engl J Med 2012, 367:1873-1875. 10.1056/NEJMp1210823, 23150955.
25. Accessed at Approval order of Wingspan stent system Food and Drug Administration website 2012, Available at: http://www.fda.gov/ohrms/dockets/dockets/05m0308/05m-0308-aav0001-approval-order-vol1.pdf. Accessed October 13, 2012, Accessed at Approval order of Wingspan stent system.
26. Gupta A, Desai MM, Kim N, Bulsara KR, Wang Y, Krumholz HM. Trends in intracranial stenting among medicare beneficiaries in the United States, 2006-2010. J Am Heart Assoc 2013, 2:e000084. 3647283, 23588099.
27. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011, 365(11):993-1003. 10.1056/NEJMoa1105335, 3552515, 21899409.
28. Kramer DB, Kesselheim AS. User fees and beyond - The FDA safety and innovation act of 2012. N Engl J Med 2012, 367:1277-1279. 10.1056/NEJMp1207800, 23034017.
29. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage alzheimer's disease. N Engl J Med 2013, 368:1169-1171. 10.1056/NEJMp1302513, 23484795.
30. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012, 366:2438-2441. 10.1056/NEJMp1205737, 22646508.
31. Dhruva Ss RRF. ACcelerated approval and possible withdrawal of midodrine. JAMA 2010, 304:2172-2173. 10.1001/jama.2010.1695, 21081731.